PMV Pharmaceuticals Doses First Patient In Global Tumor-Agnostic Phase 2 PYNNACLE Trial For Rezatapopt In TP53 Y220C-Positive Solid Tumors
PMV Pharmaceuticals Doses First Patient In Global Tumor-Agnostic Phase 2 PYNNACLE Trial For Rezatapopt In TP53 Y220C-Positive Solid Tumors
PMV Pharmicals 在針對TP53 Y220C陽性實體瘤的Rezatapopt的全球腫瘤無關的2期PYNACLE 試驗中給首位患者服藥
PMV Pharmaceuticals Doses First Patient In Global Tumor-Agnostic Phase 2 PYNNACLE Trial For Rezatapopt In TP53 Y220C-Positive Solid Tumors
PMV Pharmicals 在針對TP53 Y220C陽性實體瘤的Rezatapopt的全球腫瘤無關的2期PYNACLE 試驗中給首位患者服藥